I wrote about them shortly after I read through their IPO SEC filing in this post http://bit.ly/h9rWch
What I have a problem with is that there's not much DD out there for them other then along with $LCI, it has one of the top FDA Inspection failure rates across all pharma's according to this recent video http://bit.ly/hkwNX9
In a time of focus for major recalls due to poor facility conditions, this play gets more risky the closer to pdufa that you get cause early rejection/crl is possible..